ENTRY       D05338                      Drug
NAME        Palifermin (USAN/INN);
            Kepivance (TN)
PRODUCT     KEPIVANCE (Swedish Orphan Biovitrum AB (publ))
FORMULA     C729H1156N204O207S10
EXACT_MASS  16400.3409
MOL_WEIGHT  16410.8715
SEQUENCE    MSYDYMEGGD IRVRRLFCRT QWYLRIDKRG KVKGTQEMKN NYNIMEIRTV AVGIVAIKGV
            ESEFYLAMNK EGKLYAKKEC NEDCNFKELI LENHYNTYAS AKWTHNGGEM FVALNQKGIP
            VRGKKTKKEQ KTAHFLPMAI T
  TYPE      Peptide
REMARK      ATC code: V03AF08
            Product: D05338<US>
EFFICACY    Anti-inflammatory (oral)
COMMENT     Treatment of mucositis, Keratinocyte growth factor (KGF)
TARGET      FGFR2 (CD332) [HSA:2263] [KO:K05093]
  PATHWAY   hsa04550(2263)  Signaling pathways regulating pluripotency of stem cells
            hsa04810(2263)  Regulation of actin cytoskeleton
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             V VARIOUS
              V03 ALL OTHER THERAPEUTIC PRODUCTS
               V03A ALL OTHER THERAPEUTIC PRODUCTS
                V03AF Detoxifying agents for antineoplastic treatment
                 V03AF08 Palifermin
                  D05338  Palifermin (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antineoplastic Adjuncts/Mitigators
               Palifermin
                D05338  Palifermin (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               FGFR family
                FGFR2 (CD332)
                 D05338  Palifermin (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05338
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05338
DBLINKS     CAS: 162394-19-6
            PubChem: 47207024
            NIKKAJI: J2.317.269K
///
